Market Overview

UPDATE: Stifel Nicolaus Raises PT to $85 on Gilead Sciences on HCV Data

Share:
Related GILD
Schroer: Biotech Will Turn Around
Benzinga's Top Initiations
Following Alpha: Egerton Capital - Q4 2015 Review (Seeking Alpha)

Stifel Nicolaus maintained its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $80 to $85.

Stifel Nicolaus commented, "Twelve week sofosbuvir plus BMY's NS5a daclatasvir treatment achieved an impressive SVR4 of 98% in treatment naïve genotype 1 patients, and the same combo with ribavirin achieved a 95% SVR4. … On the Abbott investor call held last night, ABT management indicated that they expect data from its six-trial registrational program in 2013 with market launch in 2015."

Gilead Sciences closed at $73.93 on Monday.

Latest Ratings for GILD

DateFirmActionFromTo
Feb 2016OppenheimerInitiates Coverage onOutperform
Feb 2016Leerink SwannInitiates Coverage onOutperform
Feb 2016Standpoint ResearchInitiates Coverage onBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters